TriNetX rolling out new analytical tools to enable more independent research

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/utah778)
(Image: Getty/utah778)
TriNetX is releasing a series of new tools that will enable more people to conduct health research on their own, with access to rich datasets and analytics, says VP.

The company’s cloud-based platform, TNX, provides on-demand access to longitudinal clinical data and analytics capabilities.

The new capabilities – which will be rolled out later this year – build on TriNetX Research, a product line launched earlier this year​.

Alex Eastman, vice president of product management at TriNetX​, said the new analytical capabilities were developed to help researchers make use of the “vast amounts”​ of clinical data – putting health research “into the hands of more people.”

“Historically, researchers had to buy datasets and acquire or build the analytics necessary to conduct their research,”​ Eastman added.

According to the company, the new capabilities include patient journey analytics, bring your own model, and cohort monitoring.

Steve Kundrot, TriNetX CTO, said TriNetX Research is addressing the increasing trend of using real-world data (RWD) to generate real-world evidence (RWE). 

“Following the wave of digitizing medical records, the industry is looking for innovative ways to tap in to this new data asset in order to improve clinical trial design and feasibility, site selection, comparative effectiveness, safety monitoring and a whole host of other health economic outcomes research (HEOR) use cases,”​ said Kundrot.

“The industry is challenged with getting access to a rich data asset and finding the time and resources to wrangle it so that insights can be drawn,”​ he told us.

TriNetX offers access to this data asset through partnerships with more 80 healthcare organizations in 16 countries to deploy a health research network representing more than 135m.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars